[Featured Stock] Hyundai Pharm Soars on New Drug Launch News

[Asia Economy Reporter Junho Hwang] Hyundai Pharm is showing strong performance in the stock market on the 1st following the official launch of 'Hypegilsan' (active ingredient: Donepezil Hydrochloride), the first domestic tablet formulation Alzheimer's-type dementia treatment drug.

At 1:37 PM that day, Hyundai Pharm was trading at 5,770 KRW, up 1,215 KRW (26.67%) compared to the previous trading day.

Hypegilsan received product approval from the Ministry of Food and Drug Safety in April as a dementia treatment drug that can be taken by patients at all stages, from mild to severe dementia. The dosages are composed of two types: 5mg and 10mg.

A Hyundai Pharm official stated, "In the case of dementia symptom treatments, steady seller products and formulations dominate the market, so it is not easy for new products to gain attention. Products that enhance convenience through formulation differentiation find it much easier to create new markets or target niche markets, so Hypegilsan, which was launched this time, is also a product with high expectations."

This content was produced with the assistance of AI translation services.